Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 2.31
REGN's Cash-to-Debt is ranked lower than
72% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. REGN: 2.31 )
Ranked among companies with meaningful Cash-to-Debt only.
REGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.57  Med: 2.3 Max: No Debt
Current: 2.31
0.57
No Debt
Equity-to-Asset 0.70
REGN's Equity-to-Asset is ranked higher than
54% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. REGN: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
REGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.66 Max: 0.95
Current: 0.7
0.18
0.95
Debt-to-Equity 0.11
REGN's Debt-to-Equity is ranked higher than
71% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. REGN: 0.11 )
Ranked among companies with meaningful Debt-to-Equity only.
REGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.15 Max: 3.2
Current: 0.11
0
3.2
Debt-to-EBITDA 0.29
REGN's Debt-to-EBITDA is ranked higher than
82% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. REGN: 0.29 )
Ranked among companies with meaningful Debt-to-EBITDA only.
REGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.12  Med: 0.24 Max: 0.6
Current: 0.29
-2.12
0.6
Interest Coverage 92.13
REGN's Interest Coverage is ranked lower than
74% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 92.13 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 52.42 Max: 184.95
Current: 92.13
10.1
184.95
Piotroski F-Score: 7
Altman Z-Score: 10.01
Beneish M-Score: -2.36
WACC vs ROIC
12.07%
27.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 36.54
REGN's Operating Margin % is ranked higher than
94% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. REGN: 36.54 )
Ranked among companies with meaningful Operating Margin % only.
REGN' s Operating Margin % Range Over the Past 10 Years
Min: -46.02  Med: 28.3 Max: 36.54
Current: 36.54
-46.02
36.54
Net Margin % 23.54
REGN's Net Margin % is ranked higher than
88% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. REGN: 23.54 )
Ranked among companies with meaningful Net Margin % only.
REGN' s Net Margin % Range Over the Past 10 Years
Min: -49.74  Med: 13.75 Max: 54.43
Current: 23.54
-49.74
54.43
ROE % 24.49
REGN's ROE % is ranked higher than
94% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. REGN: 24.49 )
Ranked among companies with meaningful ROE % only.
REGN' s ROE % Range Over the Past 10 Years
Min: -43.76  Med: 17.76 Max: 86.68
Current: 24.49
-43.76
86.68
ROA % 16.69
REGN's ROA % is ranked higher than
94% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. REGN: 16.69 )
Ranked among companies with meaningful ROA % only.
REGN' s ROA % Range Over the Past 10 Years
Min: -18.38  Med: 11.72 Max: 44.08
Current: 16.69
-18.38
44.08
ROC (Joel Greenblatt) % 58.58
REGN's ROC (Joel Greenblatt) % is ranked higher than
93% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. REGN: 58.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
REGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -68.91  Med: 51.36 Max: 62.03
Current: 58.58
-68.91
62.03
3-Year Revenue Growth Rate 26.80
REGN's 3-Year Revenue Growth Rate is ranked higher than
78% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. REGN: 26.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
REGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25  Med: 25.3 Max: 81.1
Current: 26.8
-25
81.1
3-Year EBITDA Growth Rate 37.20
REGN's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. REGN: 37.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
REGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37 Max: 56.7
Current: 37.2
0
56.7
3-Year EPS without NRI Growth Rate 51.40
REGN's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. REGN: 51.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
REGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.5 Max: 51.4
Current: 51.4
0
51.4
GuruFocus has detected 2 Warning Signs with Regeneron Pharmaceuticals Inc REGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» REGN's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

REGN Guru Trades in Q2 2017

Mario Gabelli 492 sh (New)
Ken Fisher 1,411 sh (+75.06%)
Ron Baron 7,061 sh (+9.83%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Frank Sands 2,793,959 sh (-4.75%)
Vanguard Health Care Fund 3,255,810 sh (-10.46%)
Manning & Napier Advisors, Inc 298,778 sh (-20.54%)
Eaton Vance Worldwide Health Sciences Fund 39,536 sh (-12.95%)
» More
Q3 2017

REGN Guru Trades in Q3 2017

Ray Dalio 25,700 sh (New)
Jim Simons 93,962 sh (New)
Stanley Druckenmiller 31,800 sh (New)
Joel Greenblatt 34,175 sh (New)
Caxton Associates 600 sh (New)
Ken Fisher 1,574 sh (+11.55%)
Eaton Vance Worldwide Health Sciences Fund 39,536 sh (unchged)
Mario Gabelli 482 sh (-2.03%)
Manning & Napier Advisors, Inc 284,193 sh (-4.88%)
Ron Baron 6,673 sh (-5.49%)
Frank Sands 2,639,910 sh (-5.51%)
Vanguard Health Care Fund 2,866,296 sh (-11.96%)
» More
Q4 2017

REGN Guru Trades in Q4 2017

Pioneer Investments 70,228 sh (New)
Steven Cohen 481,354 sh (New)
Paul Tudor Jones 4,017 sh (New)
Jim Simons 579,562 sh (+516.80%)
Vanguard Health Care Fund 2,905,225 sh (+1.36%)
Ron Baron 6,673 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 39,536 sh (unchged)
Mario Gabelli Sold Out
Ray Dalio Sold Out
Caxton Associates Sold Out
Stanley Druckenmiller Sold Out
Frank Sands 2,556,612 sh (-3.16%)
Ken Fisher 1,465 sh (-6.93%)
Joel Greenblatt 4,159 sh (-87.83%)
» More
Q1 2018

REGN Guru Trades in Q1 2018

Leucadia National 5,709 sh (New)
Ray Dalio 21,872 sh (New)
Caxton Associates 1,944 sh (New)
Bill Nygren 744,000 sh (New)
Pioneer Investments 85,065 sh (+21.13%)
Vanguard Health Care Fund 3,044,325 sh (+4.79%)
Eaton Vance Worldwide Health Sciences Fund 39,536 sh (unchged)
Ron Baron Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt 4,050 sh (-2.62%)
Frank Sands 2,404,087 sh (-5.97%)
Ken Fisher 1,330 sh (-9.22%)
Jim Simons 482,470 sh (-16.75%)
Steven Cohen 199,100 sh (-58.64%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Add 4.79%0.11%$315.82 - $393.78 $ 331.97-5%3,044,325
Bill Nygren 2018-03-31 New Buy1.38%$315.82 - $393.78 $ 331.97-5%744,000
Leucadia National 2018-03-31 New Buy0.14%$315.82 - $393.78 $ 331.97-5%5,709
Joel Greenblatt 2018-03-31 Reduce -2.62%$315.82 - $393.78 $ 331.97-5%4,050
Ken Fisher 2018-03-31 Reduce -9.22%$315.82 - $393.78 $ 331.97-5%1,330
Ron Baron 2018-03-31 Sold Out 0.01%$315.82 - $393.78 $ 331.97-5%0
Vanguard Health Care Fund 2017-12-31 Add 1.36%0.03%$358.63 - $469.95 $ 331.97-18%2,905,225
Joel Greenblatt 2017-12-31 Reduce -87.83%0.19%$358.63 - $469.95 $ 331.97-18%4,159
Ken Fisher 2017-12-31 Reduce -6.93%$358.63 - $469.95 $ 331.97-18%1,465
Mario Gabelli 2017-12-31 Sold Out $358.63 - $469.95 $ 331.97-18%0
Vanguard Health Care Fund 2017-09-30 Reduce -11.96%0.41%$431.38 - $521.22 $ 331.97-30%2,866,296
Joel Greenblatt 2017-09-30 New Buy0.22%$431.38 - $521.22 $ 331.97-30%34,175
Ron Baron 2017-09-30 Reduce -5.49%$431.38 - $521.22 $ 331.97-30%6,673
Ken Fisher 2017-09-30 Add 11.55%$431.38 - $521.22 $ 331.97-30%1,574
Mario Gabelli 2017-09-30 Reduce -2.03%$431.38 - $521.22 $ 331.97-30%482
Vanguard Health Care Fund 2017-06-30 Reduce -10.46%0.33%$366.06 - $526.53 $ 331.97-24%3,255,810
Ron Baron 2017-06-30 Add 9.83%$366.06 - $526.53 $ 331.97-24%7,061
Ken Fisher 2017-06-30 Add 75.06%$366.06 - $526.53 $ 331.97-24%1,411
Mario Gabelli 2017-06-30 New Buy$366.06 - $526.53 $ 331.97-24%492
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XKRX:068270, XKRX:207940, NAS:VRTX, NAS:ALXN, HKSE:01177, LSE:SHP, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:ALNY, NAS:BGNE, NAS:JAZZ, NAS:BIIB » details
Traded in other countries:REGN.Austria, RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Headquarter Location:USA
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Bill Nygren Comments on Regeneron - Apr 06, 2018

Regeneron (NASDAQ:REGN) is a biotech company with industry-leading research and development (R&D) productivity and a proven management team. The company is led by its founder Len Schleifer who maintains a culture focused on internal development of novel new drugs. Schleifer also holds a significant equity stake in the company. Over the past decade, Regeneron has received approval for six drugs, all of which were developed in-house. Regeneron prices its drugs responsibly, and the company has never initiated a price increase. Recent drug approvals provide a strong path for long-term growth, and we expect that its largest drug, Eylea, will be sustainable for at least several more years. Regeneron spends significantly more than its peers on R&D, and its selling, general and administrative (SG&A) spending is elevated, as a result of several recent drug launches. We believe Regeneron’s R&D spending provides a great return on investment, and we expect launch costs to normalize over time. Although the company’s consensus P/E multiple appears high, if its R&D and SG&A costs are adjusted to average levels, Regeneron would trade at a low-teens P/E. We believe this is a compelling valuation for a growing business with a strong management team that is aligned with shareholders.

From Bill Nygren (Trades, Portfolio)'s first quarter 2018 Oakmark Fund commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health
New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
Bill Nygren Buys 4 New Stocks in 1st Quarter The guru’s largest new holding is Regeneron Pharmaceuticals
Bill Nygren (Trades, Portfolio), manager of the Oakmark Fund, released his first-quarter portfolio this week, listing four new holdings. Read more...
Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak
Stocks That Fell to 3-Year Lows in the Week of May 25 Allergan PLC (ACT), Walgreens Boots Alliance Inc. (WBA), Dominion Energy Inc. (D), and Regeneron Pharmaceuticals Inc. (REGN) have declined to their respective three-year lows.
Allergan PLC (NYSE:ACT), Walgreens Boots Alliance Inc. (NASDAQ:WBA), Dominion Energy Inc. (NYSE:D), and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have declined to their three-year lows. Read more...
New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma
New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
Regeneron Announces Upcoming Investor Conference Presentation
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO

Ratios

vs
industry
vs
history
PE Ratio 26.95
REGN's PE Ratio is ranked lower than
55% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. REGN: 26.95 )
Ranked among companies with meaningful PE Ratio only.
REGN' s PE Ratio Range Over the Past 10 Years
Min: 22.84  Med: 58.05 Max: 169.6
Current: 26.95
22.84
169.6
Forward PE Ratio 18.15
REGN's Forward PE Ratio is ranked higher than
69% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. REGN: 18.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.95
REGN's PE Ratio without NRI is ranked lower than
54% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. REGN: 26.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
REGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.84  Med: 58.05 Max: 169.6
Current: 26.95
22.84
169.6
Price-to-Owner-Earnings 52.74
REGN's Price-to-Owner-Earnings is ranked lower than
78% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. REGN: 52.74 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
REGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 46.27  Med: 103.75 Max: 1511.41
Current: 52.74
46.27
1511.41
PB Ratio 5.45
REGN's PB Ratio is ranked lower than
59% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. REGN: 5.45 )
Ranked among companies with meaningful PB Ratio only.
REGN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.41 Max: 26.41
Current: 5.45
2.47
26.41
PS Ratio 6.35
REGN's PS Ratio is ranked higher than
63% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 6.35 )
Ranked among companies with meaningful PS Ratio only.
REGN' s PS Ratio Range Over the Past 10 Years
Min: 3.69  Med: 10.53 Max: 24.09
Current: 6.35
3.69
24.09
Price-to-Free-Cash-Flow 30.29
REGN's Price-to-Free-Cash-Flow is ranked lower than
55% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. REGN: 30.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
REGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 26.58  Med: 78.7 Max: 1910.91
Current: 30.29
26.58
1910.91
Price-to-Operating-Cash-Flow 24.48
REGN's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. REGN: 24.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
REGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.48  Med: 46.35 Max: 358.92
Current: 24.48
21.48
358.92
EV-to-EBIT 15.47
REGN's EV-to-EBIT is ranked higher than
63% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. REGN: 15.47 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: 22.3 Max: 1948.5
Current: 15.47
-108.7
1948.5
EV-to-EBITDA 14.54
REGN's EV-to-EBITDA is ranked higher than
59% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. REGN: 14.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: 20.8 Max: 387.4
Current: 14.54
-141.9
387.4
EV-to-Revenue 5.75
REGN's EV-to-Revenue is ranked higher than
69% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. REGN: 5.75 )
Ranked among companies with meaningful EV-to-Revenue only.
REGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.2  Med: 10.25 Max: 26.7
Current: 5.75
2.2
26.7
PEG Ratio 0.85
REGN's PEG Ratio is ranked higher than
71% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. REGN: 0.85 )
Ranked among companies with meaningful PEG Ratio only.
REGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.01 Max: 1.44
Current: 0.85
0.85
1.44
Shiller PE Ratio 89.76
REGN's Shiller PE Ratio is ranked lower than
77% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. REGN: 89.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 78.72  Med: 272.85 Max: 4161.1
Current: 89.76
78.72
4161.1
Current Ratio 3.59
REGN's Current Ratio is ranked lower than
53% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. REGN: 3.59 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.13 Max: 55.65
Current: 3.59
2.17
55.65
Quick Ratio 2.94
REGN's Quick Ratio is ranked lower than
56% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. REGN: 2.94 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.17  Med: 5.85 Max: 55.65
Current: 2.94
2.17
55.65
Days Inventory 547.60
REGN's Days Inventory is ranked lower than
96% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. REGN: 547.60 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 97.79  Med: 174.05 Max: 780.78
Current: 547.6
97.79
780.78
Days Sales Outstanding 116.99
REGN's Days Sales Outstanding is ranked lower than
81% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. REGN: 116.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.9  Med: 121.88 Max: 183.53
Current: 116.99
53.9
183.53
Days Payable 177.14
REGN's Days Payable is ranked higher than
78% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. REGN: 177.14 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 131.02  Med: 168.27 Max: 2718.58
Current: 177.14
131.02
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. REGN: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -7.1 Max: -1.7
Current: -1.7
-17.9
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 20.58
REGN's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. REGN: 20.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
REGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.61  Med: 9.1 Max: 157.38
Current: 20.58
1.61
157.38
Price-to-Tangible-Book 5.45
REGN's Price-to-Tangible-Book is ranked lower than
51% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. REGN: 5.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
REGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.59 Max: 22
Current: 5.45
0.84
22
Price-to-Intrinsic-Value-Projected-FCF 2.51
REGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. REGN: 2.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
REGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.51  Med: 14.99 Max: 206.31
Current: 2.51
2.51
206.31
Price-to-Median-PS-Value 0.61
REGN's Price-to-Median-PS-Value is ranked higher than
75% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. REGN: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
REGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.1 Max: 5.07
Current: 0.61
0.21
5.07
Price-to-Peter-Lynch-Fair-Value 1.08
REGN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
54% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. REGN: 1.08 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
REGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.87  Med: 1.52 Max: 2.58
Current: 1.08
0.87
2.58
Price-to-Graham-Number 2.55
REGN's Price-to-Graham-Number is ranked lower than
52% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. REGN: 2.55 )
Ranked among companies with meaningful Price-to-Graham-Number only.
REGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 4.95 Max: 10.19
Current: 2.55
1.33
10.19
Earnings Yield (Greenblatt) % 6.46
REGN's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. REGN: 6.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
REGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19  Med: 1.6 Max: 6.9
Current: 6.46
-19
6.9
Forward Rate of Return (Yacktman) % 22.02
REGN's Forward Rate of Return (Yacktman) % is ranked higher than
84% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. REGN: 22.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
REGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: -1.2 Max: 22.3
Current: 22.02
-8
22.3

More Statistics

Revenue (TTM) (Mil) $6,064.72
EPS (TTM) $ 12.32
Beta1.55
Volatility25.68%
52-Week Range $281.89 - 543.55
Shares Outstanding (Mil)107.86

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 6,363 7,051 7,520
EBIT (Mil $) 2,213 2,582 2,719
EBITDA (Mil $) 2,457 2,882 3,071
EPS ($) 13.89 16.03 15.99
EPS without NRI ($) 13.89 16.03 15.99
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.74%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}